Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications
Authors
Guan, RuiliPurohit, Sharad
Wang, Hongjie
Bode, Bruce
Reed, John Chip
Steed, R. Dennis
Anderson, Stephen W.
Steed, Leigh
Hopkins, Diane
Xia, Chun
She, Jin-Xiong
Issue Date
2011-04-12
Metadata
Show full item recordAbstract
Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent.Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay.
Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean=242 ng/ml) compared to patients without any complications (mean=201 ng/ml) (p=3.5x10^-6). Furthermore, mean serum MCP-1 is higher in controls (mean=261 ng/ml) than T1D patients (mean=208 ng/ml) (p<10^-23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio=0.11, p<10^-33).
Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.
Citation
PLoS One. 2011 Apr 12; 6(4):e17822ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0017822
Scopus Count
Related articles
- Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the -2518 A-->G promoter polymorphism.
- Authors: Zietz B, Büchler C, Herfarth H, Müller-Ladner U, Spiegel D, Schölmerich J, Schäffler A
- Issue date: 2005 Sep
- Methylation status of CpG sites in the MCP-1 promoter is correlated to serum MCP-1 in Type 2 diabetes.
- Authors: Liu ZH, Chen LL, Deng XL, Song HJ, Liao YF, Zeng TS, Zheng J, Li HQ
- Issue date: 2012 Jun
- Study on the association between the polymorphism of MCP-1 rs1024611 and the genetic susceptibility of type 2 diabetes with sepsis.
- Authors: Li Y, He J, Shao YM, Chen L, Li M, Tang D, Shi Z, Liao Q, Guo Z, Wang J, Zheng Q, Zhao Y, Chen Y
- Issue date: 2022 Aug 12
- Monocyte chemoattractant protein-1 in spinal tuberculosis: -362G/C genetic variant and protein levels in Chinese patients.
- Authors: Guo C, Zhang H, Gao Q, He D, Tang M, Liu S, Deng A, Wang Y, Lu S, Li J, Yin X, Guo Q
- Issue date: 2014 Jan
- Monocyte chemoattractant protein 1 and macrophage migration inhibitory factor in children with type 1 diabetes.
- Authors: Ismail NA, Abd El Baky AN, Ragab S, Hamed M, Hashish MA, Shehata A
- Issue date: 2016 Jun 1